ABBV-383, a BCMA-CD3 bispecific antibody, in relapsed/refractory multiple myeloma: a multicenter, phase 1b dose optimization study with step-up dosing

被引：0

作者：

Baljevic, Muhamed ^{[1
]}

Magen, Hila ^{[2
,3
]}

Searle, Emma ^{[4
,5
]}

Jin, Ziyi ^{[6
]}

Strange, Elise ^{[6
]}

Svensson, Anders ^{[6
]}

Kumar, Shaji ^{[7
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[2] Chaim Sheba Med Ctr, Ramat Gan, Israel

[3] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[4] Christie Hosp NHS Fdn Trust, Manchester, England

[5] Univ Manchester, Manchester, England

[6] AbbVie Inc, N Chicago, IL USA

[7] Mayo Clin, Rochester, MN USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-231

引用

页码：S162 / S163

页数：2

共 50 条

[31] MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)
Levy, Moshe
Bahlis, Nizar
Raje, Noopur
Costello, Caitlin
Dholaria, Bhagirathbhai
Solh, Melhem
Tomasson, Michael
Dube, Harman
Damore, Michael
Lon, Hoi Kei
Basu, Cynthia
Skoura, Athanasia
Chan, Edward
Trudel, Suzanne
Jakubowiak, Andrzej
Chu, Michael
Gasparetto, Cristina
Dalovisio, Andrew
Sebag, Michael
Lesokhin, Alexander
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S439 - S439
[32] Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.
Sun, Mingyuan
Qiu, Lugui
Wei, Yongqiang
Jin, Jie
Li, Xin
Liu, Xue
Yin, Shaohong
Qi, Junyuan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[33] Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)
Usmani, Saad Z.
Nahi, Hareth
Mateos, Maria-Victoria
Lokhorst, Henk M.
Chari, Ajai
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Ahmadi, Tahamtan
Liu, Kevin
San-Miguel, Jesus
BLOOD, 2016, 128 (22)
[34] Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study
Chari, Ajai
Nahi, Hareth
Mateos, Maria-Victoria
Lokhorst, Henk M.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Liu, Kevin
San-Miguel, Jesus F.
Usmani, Saad Z.
BLOOD, 2017, 130
[35] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
Mohty, Mohamad
Tomasson, Michael H.
Arnulf, Bertrand
Bahlis, Nizar J.
Prince, H. Miles
Niesvizky, Ruben
Rodriguez-Otero, Paula
Martinez-Lopez, Joaquin
Koehne, Guenther
Jethava, Yogesh
Gabayan, A. Eli
Stevens, Don A.
Nooka, Ajay K.
Raje, Noopur S.
Iida, Shinsuke
Leip, Eric
Conte, Umberto
Czibere, Akos Gabor
Viqueira, Andrea
Lesokhin, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] A novel Immunotherapy Combination in relapsed/refractory Multiple Myeloma: Updated Analysis of Phase 1b Data for Talquetamab, a GPRC5DxCD3 bispecific Antibody, in Combination with Daratumumab
Kortuem, K. M.
Bahlis, N.
Mateos, M. -V.
Weisel, K.
Dholaria, B.
Garfall, A.
Goldschmidt, H.
Martin, T.
Morillo, D.
Reece, D.
Hurd, D.
Rodriguez-Otero, P.
Bhutani, M.
D'Souza, A.
Oriol, A.
Askari, E.
San-Miguel, J.
van de Donk, N.
Vishwamitra, D.
Lin, Wang S. X.
Prior, T.
Vandenberk, L.
Smit, Damiette M. -A.
Goldberg, J.
Waesch, R.
Chari, A.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 144 - 145
[37] Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels
Moreau, Philippe
Garfall, Alfred
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay
Martin, Thomas
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar
Popat, Rakesh
Besemer, Britta
Martinez Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Trancucci, Danielle
Verona, Raluca
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S477 - S478
[38] Long-term follow-up from MajesTEC-1 of Teclistamab, a B-cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Donk, Van De N. W.
Moreau, P.
Garfall, A. L.
Bhutani, M.
Oriol, A.
Nooka, A. K.
Martin, T. G.
Rosinol, L.
Mateos, M. -V.
Bahlis, N.
Popat, R.
Besemer, B.
Lopez, Martinez J.
Krishnan, A.
Delforge, M.
Trancucci, D.
Verona, R., I
Stephenson, T.
Chastain, K.
Sidana, S.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 124 - 124
[39] Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
van de Donk, Niels W. C. J.
Moreau, Philippe
Garfall, Alfred L.
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martinez-Lopez, Joaquin
Krishnan, Amrita Y.
Delforge, Michel
Trancucci, Danielle
Verona, Raluca
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[40] LEMZOPARLIMAB (TJ011133), AN ANTI-CD47 ANTIBODY, WITH/WITHOUT DEXAMETHASONE PLUS ANTI-MYELOMA REGIMENS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PHASE 1B DOSE ESCALATION AND EXPANSION STUDY
Stadtmauer, Edward
Karlin, Lionel
Weisel, Katja
Gatt, Moshe Etzion
Kansagra, Ankit
Monohan, Gregory
Yee, Andrew
Rockow-Magnone, Shayna
Cordero, Jose
Hoffman, David
Bueno, Orlando
Wu, Kevin
Gasparetto, Cristina
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A476 - A476

← 1 2 3 4 5 →